Insmed Positive Topline from Phase 2b in Pulmonary Arterial Hypertension

 –The Study Met Primary and All Secondary Efficacy Endpoints–

• Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p<0.001)
• 35.5 Meter Placebo-Adjusted Improvement in Six-Minute Walk Distance for the Secondary Efficacy Endpoint (p=0.003)
• 60% Placebo-Adjusted Reduction from Baseline in NT-proBNP Concentrations for the Secondary Efficacy Endpoint (p<0.001)
• Results Were Assessed Approximately 24 Hours After Administration, Demonstrating Sustained Benefit Throughout the 24-Hour Dosing Period

–TPIP Was Well Tolerated in the Study, with 75% of Patients Titrating to the Highest Dose–

–Insmed to Immediately Engage with FDA to Inform Phase 3 Trial Design with Studies Expected to Begin Before End of 2025 for PH-ILD and in Early 2026 for PAH–

–Insmed to Host Investor Call at 8:00 AM ET on Tuesday, June 10, 2025–

Insmed will host a conference call today at 8:00 AM ET to discuss the TPIP Phase 2b study results in PAH. The call can be accessed by dialing (888) 210-2654 (U.S. and Canada) or (646) 960-0278 (international) and entering the conference ID number 7862189. The call will also be webcast live on the Company's website at www.insmed.com. 

A replay of the conference call will be accessible approximately two hours after its completion through Tuesday, June 17, 2025, by dialing (800) 770-2030 (U.S. and Canada) or (609) 800-9909 (international) and referencing conference ID number 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at www.insmed.com. 

https://finviz.com/news/77204/insmed-announces-positive-topline-results-from-phase-2b-study-of-treprostinil-palmitil-inhalation-powder-tpip-as-once-daily-therapy-in-patients-with-pulmonary-arterial-hypertension